Cardiovascular effects of saffron: An evidence-based

Journal of Tehran University Heart Center

Volumn 6, Issue 2, 2011, Pages 59-61

  Kamalipour, Maryam ^a   Akhondzadeh, Shahin ^a  

^a TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Anti inflammatory agents; Cardiovascular agents; Crocus sativus; Lipid regulating agents; Non steriodal

Indexed keywords

CROCETIN; CROCIN; FLAVANOID; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; LYCOPENE; PLANT MEDICINAL PRODUCT; RIBOFLAVIN; SAFFRON; THIAMINE; TRIACYLGLYCEROL LIPASE; UNCLASSIFIED DRUG; VASCULAR CELL ADHESION MOLECULE 1;

ANTIINFLAMMATORY ACTIVITY; ANTIOXIDANT ACTIVITY; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR EFFECT; CROCUS; ENZYME INHIBITION; EVIDENCE BASED PRACTICE; HEART DISEASE; HEART PROTECTION; HERBAL MEDICINE; HUMAN; HYPERCHOLESTEROLEMIA; NONHUMAN; REVIEW; RISK REDUCTION;

EID: 79958215240     PISSN: 17358620     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (14)

1. Schmidt M, Betti G, Hensel A. Saffron in phytotherapy: pharmacology and clinical uses. Wien Med Wochenschr 2007;157:315-319.
2. Bathaie SZ, Mousavi SZ. New applications and mechanisms of action of saffron and its important ingredients. Crit Rev Food Sci Nutr 2010;50:761-786.
3. Akhondzadeh S, Tahmacebi-Pour N, Noorbala AA, Amini H, Fallah-Pour H, Jamshidi AH, Khani M. Crocus sativus L. in the treatment of mild to moderate depression: a double-blind, randomized and placebo controlled trial. Phytother Res 2005;19:148-151.
4. Noorbala AA, Akhondzadeh S, Tahmacebi-Pour N, Jamshidi AH. Hydroalcoholic extract of Crocus sativus L. versus fluoxetine in the treatment of mild to moderate depression: a double-blind, randomized pilot trial. J Ethnopharmacol 2005;97:281-284.
5. Moshiri E, Basti AA, Noorbala AA, Jamshidi AH, Abbasi S, Akhondzadeh SH. Crocus sativus L. (petal) in the treatment of mild-to-moderate depression: a double-blind, randomized and placebo controlled trial. Phytomedicine 2006;13:607-611.
6. Akhondzadeh Basti A, Moshiri E, Noorbala AA, Jamshidi AH, Abbasi SH, Akhondzadeh S. Comparison of petal of Crocus sativus L. and fluoxetine in the treatment of depressed outpatients: a pilot double-blind randomized trial. Prog Neuropsychopharmacol Biol Psychiatry 2007;31:439-442.
7. Agha-Hosseini M, Kashani L, Aleyaseen A, Ghoreishi A, Rahmanpour H, Zarrinara AR, Akhondzadeh S. Crocus sativus L. (saffron) in the treatment of premenstrual syndrome: a double-blind, randomised and placebo controlled trial. BJOG 2008;115:515-519.
8. Akhondzadeh S, Sabet MS, Harirchian MH, Togha M, Cheraghmakani H, Razeghi S, Hejazi SS, Yousefi MH, Alimardani R, Jamshidi A, Zare F, Moradi A. Saffron in the treatment of patients with mild to moderate Alzheimer's disease: a 16-week, randomized and placebo-controlled trial. J Clin Pharm Ther 2010;35:581-588.
9. Akhondzadeh S, Shafiee Sabet M, Harirchian MH, Togha M, Cheraghmakani H, Razeghi S, Hejazi SS, Yousefi MH, Alimardani R, Jamshidi A, Rezazadeh SA, Yousefi A, Zare F, Moradi A, Vossoughi A. A 22-week, multicenter, randomized, doubleblind controlled trial of Crocus sativus in the treatment of mildto-moderate Alzheimer's disease. Psychopharmacology (Berl) 2010;207:637-643.
10. Verma SK, Bordia A. Antioxidant property of Saffron in man. Indian J Med Sci 1998;52:205-207.
11. Basker D, Negbi M. The use of saffron. Econ Bot 1983;37:228-236.
12. Zarghami NS, Heinz DE. Monoterpene aldehydes and isophorone 337 related compounds of saffron. Phytochemistry 1971;10:2755-2761.
13. Zheng S, Qian Z, Tang F, Sheng L. Suppression of vascular cell adhesion molecule-1 expression by crocetin contributes to attenuation of atherosclerosis in hypercholesterolemic rabbits. Biochem Pharmacol 2005;70:1192-1199.
14. Sheng L, Qian Z, Zheng S, Xi L. Mechanism of hypolipidemic effect of crocin in rats: crocin inhibits pancreatic lipase. Eur J Pharmacol 2006;543:116-122.